# Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

> **NCT02597127** · PHASE2 · COMPLETED · sponsor: **The Medicines Company** · enrollment: 501 (actual)

## Conditions studied

- Atherosclerotic Cardiovascular Disease
- Familial Hypercholesterolemia
- Diabetes

## Interventions

- **DRUG:** ALN-PCSSC
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT02597127
- **Lead sponsor:** The Medicines Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2017-06-07
- **Final completion:** 2017-06-07
- **Target enrollment:** 501 (ACTUAL)
- **Last updated:** 2019-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02597127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02597127, "Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02597127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*